Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme

Neurocognitive Deficits After Radiation Therapy for Brain Malignancies

(2015) Shumaila Saad et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

“Right-to-Try” Legislation: Progress or Peril?

(2015) Y. Tony Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

CNS Anticancer Drug Discovery and Development Conference White Paper

(2015) Victor A. Levin et al.   NEURO-ONCOLOGY

Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)

(2015) Andrew B. Lassman et al.   NEURO-ONCOLOGY

Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses

(2015) Danielle N. Renner et al.   PLoS One

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme

(2015) Hayley Nehoff et al.   Oncotarget

Improvement in treatment results of glioblastoma over the last three decades and beneficial factors

(2014) Hiroto Kawano et al.   BRITISH JOURNAL OF NEUROSURGERY

Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma

(2014) Jennie W. Taylor et al.   JOURNAL OF NEURO-ONCOLOGY

The blood-brain barrier: Structure, function and therapeutic approaches to cross it

(2014) Marta Tajes et al.   MOLECULAR MEMBRANE BIOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib

(2013) B. D. Furmanski et al.   CLINICAL CANCER RESEARCH

Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression

(2013) SEBASTIEN TAURIN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?

(2012) Sebastien Taurin et al.   JOURNAL OF CONTROLLED RELEASE

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

(2012) E. Franceschi et al.   NEURO-ONCOLOGY

Caveolin-1, caveolae, and glioblastoma

(2012) M.-O. Parat et al.   NEURO-ONCOLOGY

An Allograft Glioma Model Reveals the Dependence of Aquaporin-4 Expression on the Brain Microenvironment

(2012) Susan Noell et al.   PLoS One

Current Review of in Vivo GBM Rodent Models: Emphasis on the CNS-1 Tumour Model

(2011) Valerie L. Jacobs et al.   ASN Neuro

Targeting apoptosis pathways in glioblastoma

(2011) Günter Eisele et al.   CANCER LETTERS

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation

(2011) K Vandyke et al.   Blood Cancer Journal

A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry

(2010) S. El Hallani et al.   BRAIN

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor

(2010) A. H. Stegh et al.   GENES & DEVELOPMENT

Vasculogenic mimicry–potential target for glioblastoma therapy: an in vitro and in vivo study

(2010) Yinsheng Chen et al.   MEDICAL ONCOLOGY

Understanding and overcoming major barriers in cancer nanomedicine

(2010) Shuming Nie   Nanomedicine

Molecular Therapeutic Targets for Glioma Angiogenesis

(2010) Shingo Takano et al.   Journal of Oncology

Convection-enhanced delivery of nanocarriers for the treatment of brain tumors

(2009) Emilie Allard et al.   BIOMATERIALS

Prognostic significance of c-Met expression in glioblastomas

(2008) Doo-Sik Kong et al.   CANCER

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

(2008) D. K. Hiwase et al.   CLINICAL CANCER RESEARCH

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION